Huang Zhenjun, Yu Chengpeng, Yu Liqing, Shu Hongxin, Zhu Xianhua
Department of Vascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Second Clinical Medical College, Nanchang University, Nanchang, China.
Front Oncol. 2022 May 24;12:887828. doi: 10.3389/fonc.2022.887828. eCollection 2022.
The four and a half LIM domain protein 3, also named the LIM-protein FHL3, belongs to the LIM-only family. Based on the special structure of LIM-only proteins, FHL3 can perform significant functions in muscle proliferation and cardiovascular diseases by regulating cell growth and signal transduction. In recent years, there has been increasing evidence of a relation between FHLs and tumor biology, since FHL3 is often overexpressed or downregulated in different cancers. On the one hand, FHL3 can function as a tumor suppressor and influence the expression of downstream genes. On the other hand, FHL3 can also play a role as an oncoprotein in some cancers to promote tumor progression phosphorylation. Thus, FHL3 is proposed to have a dual effect on cancer progression, reflecting its complex roles in cancer. This review focuses on the roles of FHL3 in cancer progression and discusses the interaction of FHL3 with other proteins and transcription factors. Finally, the clinical significance of FHL3 for the treatment of cancers is discussed.
四又二分之一LIM结构域蛋白3，也称为LIM蛋白FHL3，属于仅含LIM结构域的蛋白家族。基于仅含LIM结构域蛋白的特殊结构，FHL3可通过调节细胞生长和信号转导在肌肉增殖和心血管疾病中发挥重要作用。近年来，越来越多的证据表明FHL蛋白与肿瘤生物学之间存在关联，因为FHL3在不同癌症中常出现过表达或下调。一方面，FHL3可作为肿瘤抑制因子发挥作用并影响下游基因的表达。另一方面，FHL3在某些癌症中也可作为癌蛋白促进肿瘤进展磷酸化。因此，FHL3被认为对癌症进展具有双重作用，反映了其在癌症中的复杂作用。本综述重点关注FHL3在癌症进展中的作用，并讨论FHL3与其他蛋白质和转录因子的相互作用。最后，探讨了FHL3在癌症治疗中的临床意义。
